Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug

Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug Publisher Pubmed

Shohani S¹ ; Mondanizadeh M¹ ; Abdoli A² ; Khansarinejad B³ ; Salimiasl M⁴ ; Ardestani MS⁵ ; Ghanbari M⁶ ; Haj MS⁷ ; Zabihollahi R²

Show Affiliations

1. Department of Biotechnology and Molecular Medicine, Faculty of Medicine, Arak University of Medical Science, Arak, Iran
2. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
3. Department of Microbiology and Immunology, Faculty of Medicine, Arak University of Medical Science, Arak, Iran
4. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
5. Department of Radiopharmacy, Tehran Medical Sciences University, Tehran, Iran
6. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran
7. Department of Virology, Faculty of Medicine, Jundishapour University of Medical Science, Ahvaz, Iran

Source: Current HIV Research Published:2017

Abstract

Highly active antiretroviral therapy (HAART) has been commonly used for HIV treatment. Its main drawbacks like drug resistance and side effects raised researcher’s interest to find new approaches for its treatment. Trimethyl chitosan is one of the drug carriers which has been introduced recently. Materials and Methods: the conjugated atripla-trimethyl chitosan was designed and characterized by zetasizer, AFM and FTIR techniques. The drug conjugation with trimethyl chitosan and cellular uptake of nano-conjugate were determined by spectrophotometry. XTT test was used to measure the cytotoxicity. Anti-retroviral efficiency was studied by ELISA test. Results: Zetasizer Results proved that the average size of nano-conjugate particles agglomeration was 493.4±24.6 nm but the size of the majority of the particles was 177.2±7.8 nm with the intensity of 87.9%. AFM technique revealed that the sizes of nano-conjugate and trimethyl chitosan were 129 nm and 59.78 nm, respectively. Zeta potential was -1.35±0.04 mv for nano-conjugate and -7.69±0.3 mv for drug. Conjugation efficiency of atripla with trimethyl chitosan was 5.27%. Measured cellular uptake with spectrophotometry for nano-conjugate was about twice of the free drug in examined concentrations (P=0.007). Compared to atripla, the nano-conjugate showed a higher inhibitory effect on HIV replication (P=0.0001). Conclusion: The result showed that atripla-TMC conjugate does not have a significant cytotoxicity effect. Due to the higher inhibitory effect of nano-conjugate on viral replication, it can be used in lower concentration for antiviral treatment, which resulted in reduction of drug resistance and other side effects. © 2017 Bentham Science Publishers.

Related Docs

View other Related Docs

1. Uptake and Transport of Insulin Across Intestinal Membrane Model Using Trimethyl Chitosan Coated Insulin Niosomes, Materials Science and Engineering C (2015)

2. Chitosan-Based Smart Stimuli-Responsive Nanoparticles for Gene Delivery and Gene Therapy: Recent Progresses on Cancer Therapy, International Journal of Biological Macromolecules (2024)

3. Preparation and Optimization of N-Trimethyl-O-Carboxymethyl Chitosan Nanoparticles for Delivery of Low-Molecular-Weight Heparin, Pharmaceutical Development and Technology (2016)

4. A Novel Nanoemulsion-Based Method to Produce Ultrasmall, Water-Dispersible Nanoparticles From Chitosan, Surface Modified With Cell-Penetrating Peptide for Oral Delivery of Proteins and Peptides, International Journal of Nanomedicine (2017)

5. Chitosan As a Machine for Biomolecule Delivery: A Review, Carbohydrate Polymers (2021)

6. Codelivery of Stat3 Sirna and Bv6 by Carboxymethyl Dextran Trimethyl Chitosan Nanoparticles Suppresses Cancer Cell Progression, International Journal of Pharmaceutics (2020)

7. Preparation, Evaluation and Optimization of Nanoparticles Composed of Thiolated Triethyl Chitosan: A Potential Approach for Buccal Delivery of Insulin, Journal of Drug Delivery Science and Technology (2018)

8. In-Vitro and In-Vivo Cytotoxicity and Efficacy Evaluation of Novel Glycyl-Glycine and Alanyl-Alanine Conjugates of Chitosan and Trimethyl Chitosan Nano-Particles As Carriers for Oral Insulin Delivery, International Journal of Pharmaceutics (2018)

Experts (# of related papers)

View all Related Experts

Farid Dorkoosh (5)

Mohsen Amini (2)

Style	Citing Format
MLA	Shohani S, et al.. "Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug." Current HIV Research, vol. 15, no. 1, 2017, pp. 56-65.
APA	Shohani S, Mondanizadeh M, Abdoli A, Khansarinejad B, Salimiasl M, Ardestani MS, Ghanbari M, Haj MS, Zabihollahi R (2017). Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug. Current HIV Research, 15(1), 56-65.
Chicago	Shohani S, Mondanizadeh M, Abdoli A, Khansarinejad B, Salimiasl M, Ardestani MS, Ghanbari M, Haj MS, Zabihollahi R. "Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug." Current HIV Research 15, no. 1 (2017): 56-65.
Harvard	Shohani S et al. (2017) 'Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug', Current HIV Research, 15(1), pp. 56-65.
Vancouver	Shohani S, Mondanizadeh M, Abdoli A, Khansarinejad B, Salimiasl M, Ardestani MS, et al.. Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug. Current HIV Research. 2017;15(1):56-65.
BibTex	@article{ author = {Shohani S and Mondanizadeh M and Abdoli A and Khansarinejad B and Salimiasl M and Ardestani MS and Ghanbari M and Haj MS and Zabihollahi R}, title = {Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug}, journal = {Current HIV Research}, volume = {15}, number = {1}, pages = {56-65}, year = {2017} }
RIS	TY - JOUR AU - Shohani S AU - Mondanizadeh M AU - Abdoli A AU - Khansarinejad B AU - Salimiasl M AU - Ardestani MS AU - Ghanbari M AU - Haj MS AU - Zabihollahi R TI - Trimethyl Chitosan Improves Anti-Hiv Effects of Atripla As a New Nanoformulated Drug JO - Current HIV Research VL - 15 IS - 1 SP - 56 EP - 65 PY - 2017 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract